The drug Cytokinetics is placing its hopes on is aficamten, a selective small-molecule inhibitor of cardiac myosin. The drug ...

Hypertrophic cardiomyopathy (HCM) was first described in the late 1950s as a disease typified by substantial thickening of the myocardium, particularly the left ventricular wall, with no overt cause.

But in some cases, they may need additional tests to confirm a diagnosis, such as: The primary goals of treatment for HCM are ...

Researchers from Affinia Therapeutics Inc. have described the development and preclinical evaluation of a new AAV-based gene therapy, designed using a novel cardiotropic capsid, for the potential ...

Hypertrophic cardiomyopathy (HCM) is an uncommon disease with significant consequences. Since the 1950s, major strides in understanding its etiology and pathogenesis have led to improved ...

Opens in a new tab or window A small panel of circulating biomarkers may reliably distinguish hypertrophic cardiomyopathy (HCM) from similar conditions that cause left ventricular hypertrophy (LVH ...

With its first AAV gene therapy program, DiNA-001, in development for the treatment of MYBPC3 hypertrophic cardiomyopathy (HCM), the company and its platform is attracting significant partnering ...

A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

TN-201 is being developed for the potential treatment of MYBPC3-associated hypertrophic cardiomyopathy (HCM), a condition caused by insufficient levels of myosin-binding protein C (MyBP-C).

View the full release here: "We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," ...

Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now ...

"Our latest clinical trial results suggest aficamten is a promising treatment for HCM." HCM affects about 1 in 500 people and is one of the most common causes of sudden death for youth and ...